GH Research Shares Soar 6.98% on FDA Response

GH Research (GHRS) shares surged 6.98% today, reaching their highest level since February 2025 with an intraday gain of 7.39%.

GH Research recently submitted a complete response to the US FDA regarding the clinical hold on its Investigational New Drug (IND). This move is crucial as it addresses regulatory hurdles that the company is currently navigating, which can significantly influence investor sentiment and stock performance.

In the past month, GH Research's stock has experienced volatility, with a notable decline of 4.6% on June 10, 2025. This fluctuation could be attributed to market reactions to ongoing developments with the company's IND or broader market conditions affecting the biotech sector.